apollo
0
  1. Home
  2. Medicine
  3. Ryverna 10Mg/ ml Inj 10 ml

Written By Bayyarapu Mahesh Kumar , M Pharmacy
Reviewed By Dr Aneela Siddabathuni , MPharma., PhD
Non returnable*
COD available

Online payment accepted

rxMedicinePrescription drug

Whats That

tooltip

Composition :

CRIZANLIZUMAB-100MG

Manufacturer/Marketer :

Novartis India Ltd

Consume Type :

PARENTERAL

Return Policy :

Not Returnable

Expires on or after :

About Ryverna 10Mg/ml Inj

Ryverna 10Mg/ml Inj belongs to the group of medicines called monoclonal antibodies, which is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells obstruct blood flow to the point where tissues are deprived of oxygen. This, in turn, causes an inflammatory reaction. The outcome is severe pain, which can affect any part of the body but is most typically felt in the back, chest, or extremities.

Ryverna 10Mg/ml Inj contains Crizanlizumab-tmca, which works by blocking certain blood cells from interacting.

Ryverna 10Mg/ml Inj will be administered by a healthcare professional; do not self-administer. Your doctor will decide the dose and duration based on your medical condition. In some cases, Ryverna 10Mg/ml Inj may cause Infusion site reactions, nausea, arthralgia (pain in a joint), back pain, and pyrexia (fever). Most of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen.

Before taking the Ryverna 10Mg/ml Inj, let your doctor know about all your medical conditions, sensitivities, and medications you are using. Ryverna 10Mg/ml Inj may cause fetal harm. So, inform your doctor if you are pregnant and planning to become pregnant. Do not breastfeed while on medication unless recommended by the doctor. Ryverna 10Mg/ml Inj is not recommended for children below 16 years as the safety and effectiveness have not been established. Consumption of alcohol is not recommended while on therapy.

Uses of Ryverna 10Mg/ml Inj

Vaso-Occlusive Crises (VOCs)

Directions for Use

Ryverna 10Mg/ml Inj will be administered by a healthcare professional; do not self-administer.

Medicinal Benefits

Ryverna 10Mg/ml Inj contains Crizanlizumab-tmca, which belongs to the group of medicines called monoclonal antibodies and is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Crizanlizumab-tmca which works by binding to the protein P-selectin in the blood. This protein is responsible for the adhesion of blood cells. By inhibiting P-selectin, blood cell limitations are avoided, and blood supply throughout the body is improved.

Storage

Store in a cool and dry place away from sunlight

Drug Warnings

Before using the Ryverna 10Mg/ml Inj, inform your doctor about your medical conditions (e.g., pregnancy, nursing, any scheduled surgery, etc.), sensitivities (allergic reactions to foods and medicines), and medications you are taking. Other drugs (especially corticosteroids) or supplements should not be taken with Ryverna 10Mg/ml Inj unless prescribed by a doctor. Do not miss any doses and finish the entire course of medicine. Stopping the drug too soon may cause the infection to reoccur or worsen.

Diet & Lifestyle Advise

  • A healthy diet is good for everyone, but it's especially crucial for those with sickle cell disease (SCD). Low levels of important nutrients such as proteins, minerals, and vitamins have been related to SCD.
  • Adopting a diet that is high in protein and other nutrients can help lessen discomfort and other SCD consequences.
  • Sickle cell disease patients should drink 8 to 10 glasses of water every day and eat nutritious foods. Try to stay cool, chilly, and energized.
  • A healthy diet high in zinc, folate, and water may assist in reducing the condition's consequences.

Habit Forming

No

Therapeutic Class

MONOCLONAL ANTIBODIES

FAQs

Ryverna 10Mg/ml Inj contains Crizanlizumab-tmca which works by binding to the protein P-selectin in the blood. This protein is responsible for the adhesion of blood cells. By inhibiting P-selectin, blood cell limitations are avoided, and blood supply throughout the body is improved.

Infusion-related reactions may develop in some circumstances. If you experience any signs and symptoms, your doctor will discontinue the infusion and take necessary action accordingly.

Sickle cell disease is caused by a gene that alters the development of red blood cells.

No, it is indicated to reduce the frequency of vaso-occlusive crises (VOCs) with sickle cell disease.

The only cure for sickle cell disease is a stem cell or bone marrow transplant, which is rarely performed due to the complications involved.

Drug-Drug Interactions Checker List

  • EFGARTIGIMOD ALFA
  • ROZANOLIXIZUMAB

Special Advise

  • Platelet Counts should be evaluated on a regular basis throughout Ryverna 10Mg/ml Inj treatment and until full recovery is achieved.

Disease/Condition Glossary

A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells obstruct blood flow to the point where tissues are deprived of oxygen. This, in turn, causes an inflammatory reaction. The outcome is severe pain, which can affect any body part but is most typically felt in the back, chest, or extremities.

Have a query?

whatsapp Floating Button